Skip to content
Review Open access

Platelet-activating factor in multiple sclerosis: From peripheral inflammation to central neurodegeneration.

Sep 2026 · Multiple Sclerosis and Related Disorders · Vol 115, pp. 107922 · 0 citations · 41 references
Medicine

TL;DR

PAF/PAF-R targeting remains a mechanistically promising but clinically unestablished therapeutic approach requiring further translational investigation, and some detrimental effects of PAF appear to occur independently of PAF-R.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease in which peripheral immune activation, blood-brain barrier (BBB) dysfunction, and central nervous system (CNS) injury are closely interconnected. Platelet-activating factor (PAF) is a potent phospholipid mediator involved in inflammation, platelet activation, oxidative stress, and neuronal signaling. Increased PAF levels in the plasma and cerebrospinal fluid (CSF) of patients with MS suggest its involvement in both peripheral and central disease processes. Clinical and experimental evidence supports a working model in which peripheral platelet and neurovascular activation may interact with central PAF/PAF receptor (PAF-R) signaling, where microglial-neuronal communication, glutamate/NMDA-mediated excitotoxicity, synaptic injury, and demyelination may contribute to neural damage. Altered regulation of PAF activity may further enhance these processes. However, several mechanistic links remain derived from experimental models, and some detrimental effects of PAF appear to occur independently of PAF-R. This review integrates the evidence supporting a peripheral-to-central PAF framework in MS and critically evaluates direct PAF-R antagonists, indirect PAF modulators, and exploratory PAF-related candidates. Overall, PAF/PAF-R targeting remains a mechanistically promising but clinically unestablished therapeutic approach requiring further translational investigation.

Read PDF

Similar papers

Review Sep 2026

Activated platelets in multiple sclerosis: Immunoinflammatory mechanisms and the therapeutic controversy of acetylsalicylic acid.

A narrative review explores how platelet activation may contribute to MS through blood-brain barrier dysfunction, immune-cell recruitment, oxidative stress, demyelination, and neurodegeneration, and critically examines acetylsalicylic acid (ASA) as a potential platelet-targeted strategy.

H. Al-Jehani, Hayder M. Al-kuraishy, Weam A. Elkady et al. · 0 citations
Review Open access Sep 2026

Blood–brain barrier dysfunction and peripheral immune activation in Alzheimer’s disease: an inflammation-centered review

An inflammation-centered model is proposed in which BBB breakdown and peripheral immune dysregulation form a pathogenic loop that accelerates neurodegeneration, and targeting this BBB–peripheral immune axis may provide new opportunities for biomarker development, patient stratification, and combination therapy beyond c...

Zu-Li Yang, Zhi-Qiang Xiao, Bin Huang et al. · 0 citations
Open access Sep 2026

Intracellular complement factor H protects neurons during CNS inflammation

Using single-nucleus RNA-sequencing analysis of RGCs from donors with MS and control individuals, it is found that CFH expression was strongly correlated with intrinsic resilience to RGC degeneration and reveals a non-canonical intracellular function of CFH in neurons.

Christina Mayer, Marcel S. Woo, J. Sonner et al. · 0 citations
Review Open access Sep 2026

The Role of Mast Cells and Their Potential as a Therapeutic Target For Neuroinflammation

Abstract Neuroinflammation is increasingly recognized as a central mechanism underlying the onset and progression of numerous neurological disorders, including neurodegenerative, autoimmune, and cerebrovascular diseases. Although microglia and astrocytes are traditionally considered the primary mediators of inflammator...

S. Scuderi, R. Basilotta, L. Cucinotta et al. · 0 citations
Review 2026

Microglia extracellular traps (MiETs) in Neurodegeneration: Mechanisms, Evidence Gaps, and Untapped Therapeutic Promise.

This work situates MiET formation within the broader microglial functional repertoire and focuses on how ET-dominant responses may compromise homeostatic or neuroprotective roles, expanding the conceptual framework for microglial pathogenicity and inviting future mechanistic and translational research.

Lipika Sha, Sushmita Jha · 0 citations
Review Oct 2026

Neuroinflammation as a Final Common Pathway in Systemic Disease — How Systemic Disease Becomes Brain Disease

Recognizing neuroinflammation as this final common pathway reframes diagnosis around shared biomarkers rather than disease labels, predicts cross-disease therapeutic benefit, and relocates the therapeutic window earlier—toward protecting a brain vulnerable long before overt neurological disease declares itself.

A. A. Gaitan, Annelise Velasco de Azevedo-Pereira, Javier M. Romero et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.